Review



cd34 positive cd34 cells  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Miltenyi Biotec cd34 positive cd34 cells
    BMMC samples derived from AML and MDS patients were treated with 0–500 pM of AFM28, a non-targeting control (RSV/CD16A) or an Fc-enhanced anti-CD123 IgG antibody for 24 h in the presence of IL-2-preincubated allogeneic healthy donor NK cells, all derived from different donors, at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45 low <t>/CD34</t> + or CD33 + /CD38 + /CD123 + cells. The gating strategy is shown in Supplementary Fig. . Cell counts of 0 pM treatment were set to baseline. A – D Concentration-dependent lysis of blasts from AML ( A , B , n = 10) or MDS ( C , D , n = 5) patients by AFM28 compared to RSV/CD16A. E – H Concentration-dependent lysis of blasts from AML patients with low ( E , F , n = 5) or high ( G , H , n = 5) CD64 MFI by AFM28 compared to an Fc-enhanced anti-CD123 IgG antibody. Data in ( A , C , E and G ) are represented as mean ± SD. Data in ( B , D , F and H ) were analyzed using two-way ANOVA and Šídák’s multiple comparisons test. MFI median fluorescence intensity; SD standard deviation.
    Cd34 Positive Cd34 Cells, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pmc12371032-271-2-16
    Average 95 stars, based on 3 article reviews
    cd34 positive cd34 cells - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "The bispecific innate cell engager AFM28 eliminates CD123 + leukemic stem and progenitor cells in AML and MDS"

    Article Title: The bispecific innate cell engager AFM28 eliminates CD123 + leukemic stem and progenitor cells in AML and MDS

    Journal: Nature Communications

    doi: 10.1038/s41467-025-63069-y

    BMMC samples derived from AML and MDS patients were treated with 0–500 pM of AFM28, a non-targeting control (RSV/CD16A) or an Fc-enhanced anti-CD123 IgG antibody for 24 h in the presence of IL-2-preincubated allogeneic healthy donor NK cells, all derived from different donors, at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45 low /CD34 + or CD33 + /CD38 + /CD123 + cells. The gating strategy is shown in Supplementary Fig. . Cell counts of 0 pM treatment were set to baseline. A – D Concentration-dependent lysis of blasts from AML ( A , B , n = 10) or MDS ( C , D , n = 5) patients by AFM28 compared to RSV/CD16A. E – H Concentration-dependent lysis of blasts from AML patients with low ( E , F , n = 5) or high ( G , H , n = 5) CD64 MFI by AFM28 compared to an Fc-enhanced anti-CD123 IgG antibody. Data in ( A , C , E and G ) are represented as mean ± SD. Data in ( B , D , F and H ) were analyzed using two-way ANOVA and Šídák’s multiple comparisons test. MFI median fluorescence intensity; SD standard deviation.
    Figure Legend Snippet: BMMC samples derived from AML and MDS patients were treated with 0–500 pM of AFM28, a non-targeting control (RSV/CD16A) or an Fc-enhanced anti-CD123 IgG antibody for 24 h in the presence of IL-2-preincubated allogeneic healthy donor NK cells, all derived from different donors, at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45 low /CD34 + or CD33 + /CD38 + /CD123 + cells. The gating strategy is shown in Supplementary Fig. . Cell counts of 0 pM treatment were set to baseline. A – D Concentration-dependent lysis of blasts from AML ( A , B , n = 10) or MDS ( C , D , n = 5) patients by AFM28 compared to RSV/CD16A. E – H Concentration-dependent lysis of blasts from AML patients with low ( E , F , n = 5) or high ( G , H , n = 5) CD64 MFI by AFM28 compared to an Fc-enhanced anti-CD123 IgG antibody. Data in ( A , C , E and G ) are represented as mean ± SD. Data in ( B , D , F and H ) were analyzed using two-way ANOVA and Šídák’s multiple comparisons test. MFI median fluorescence intensity; SD standard deviation.

    Techniques Used: Derivative Assay, Control, Flow Cytometry, Concentration Assay, Lysis, Fluorescence, Standard Deviation

    BMMC patient-derived AML and MDS samples were treated with or without 100 pM of AFM28 for 24 h in the presence of IL-2-preincubated allogeneic NK cells, all derived from different donors, at an E:T ratio of 1:1. Analysis was performed using flow cytometry. LSPCs were defined as viable/CD45 low /CD34 + /CD38 − /CD117 + cells. The gating strategy is shown in Supplementary Fig. . Cell counts of 0 pM treatment for LSPCs and CD123 + LSPCs were set to baseline. A Representative dot plot of LSPC lysis following treatment with 100 pM AFM28 or without AFM28 (indicated as 0 pM) of one AML patient sample. B , C Lysis of LSPCs from AML patients ( B , n = 5) and from MDS patients ( C , n = 5) in the presence of 100 pM AFM28 or without AFM28. Data are represented as mean ± SD and were analyzed using one-way and two-way ANOVA and Šídák’s multiple comparisons test. D , Schematic workflow of the CFU assay. Created in BioRender ( https://BioRender.com/8l2brjy ). E – G CFU assay results of AML ( E , n = 5), MDS ( F , n = 5) and healthy ( G , n = 5) CD34 + cell samples treated with 0/10/100/1000 pM of AFM28 for 24 h in the presence of allogeneic NK cells at an E:T ratio of 1:1. “CD34 + only” describes culturing untreated CD34 + cells without allogeneic NK cells. Colonies were counted manually. Colony count of “CD34 + only” condition was normalized to 100%. Data are represented as mean ± SD and were analyzed using one-way ANOVA and Tukey’s multiple comparisons test. SD standard deviation.
    Figure Legend Snippet: BMMC patient-derived AML and MDS samples were treated with or without 100 pM of AFM28 for 24 h in the presence of IL-2-preincubated allogeneic NK cells, all derived from different donors, at an E:T ratio of 1:1. Analysis was performed using flow cytometry. LSPCs were defined as viable/CD45 low /CD34 + /CD38 − /CD117 + cells. The gating strategy is shown in Supplementary Fig. . Cell counts of 0 pM treatment for LSPCs and CD123 + LSPCs were set to baseline. A Representative dot plot of LSPC lysis following treatment with 100 pM AFM28 or without AFM28 (indicated as 0 pM) of one AML patient sample. B , C Lysis of LSPCs from AML patients ( B , n = 5) and from MDS patients ( C , n = 5) in the presence of 100 pM AFM28 or without AFM28. Data are represented as mean ± SD and were analyzed using one-way and two-way ANOVA and Šídák’s multiple comparisons test. D , Schematic workflow of the CFU assay. Created in BioRender ( https://BioRender.com/8l2brjy ). E – G CFU assay results of AML ( E , n = 5), MDS ( F , n = 5) and healthy ( G , n = 5) CD34 + cell samples treated with 0/10/100/1000 pM of AFM28 for 24 h in the presence of allogeneic NK cells at an E:T ratio of 1:1. “CD34 + only” describes culturing untreated CD34 + cells without allogeneic NK cells. Colonies were counted manually. Colony count of “CD34 + only” condition was normalized to 100%. Data are represented as mean ± SD and were analyzed using one-way ANOVA and Tukey’s multiple comparisons test. SD standard deviation.

    Techniques Used: Derivative Assay, Flow Cytometry, Lysis, Colony-forming Unit Assay, Standard Deviation

    A Fresh whole blood samples from newly diagnosed AML patients ( n = 6) were treated with AFM28 (0/0.01/1 µg/ml equivalent to 0/50/5000 pM) or vehicle in the absence (circles) or presence of healthy donor-derived allogeneic NK cells (squares: fresh, non-expanded NK cells; triangles: cryopreserved cytokine-expanded NK cells generated by a standardized protocol, see Supplementary Methods and Supplementary Fig. ), all derived from different donors, for 24 h at an E:T ratio (NK cells:peripheral leukocytes) of 1:1. Blasts were defined as viable/CD45 low /CD123 + /CD33 + /CD117 + or CD34 + /CD117 + . The gating strategy is shown in Supplementary Fig. . Leukemic blast counts of vehicle treatment without NK cells were set to baseline. E:T ratios of patient’s endogenous NK cells to blasts (in the absence of healthy donor-derived allogeneic NK cells) were 0.1:1, 0.01:1 and 0.2:1 for non-responders and 0.5:1, 0.1:1 and 0.1:1 for responders (data points from top to bottom for 5000 pM AFM28). Data are represented as mean ± SD and were analyzed using one-way ANOVA and Tukey’s multiple comparisons test. B BMMC samples derived from a single AML patient were treated with 0–500 pM of AFM28 for 24 h in the presence of allogeneic AML patient-derived NK cells ( n = 5) or healthy donor-derived NK cells ( n = 5) at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45 low /CD34 + /CD38 + /CD123 + . Blast counts of 0 pM treatment were set to baseline. HY healthy, SD standard deviation.
    Figure Legend Snippet: A Fresh whole blood samples from newly diagnosed AML patients ( n = 6) were treated with AFM28 (0/0.01/1 µg/ml equivalent to 0/50/5000 pM) or vehicle in the absence (circles) or presence of healthy donor-derived allogeneic NK cells (squares: fresh, non-expanded NK cells; triangles: cryopreserved cytokine-expanded NK cells generated by a standardized protocol, see Supplementary Methods and Supplementary Fig. ), all derived from different donors, for 24 h at an E:T ratio (NK cells:peripheral leukocytes) of 1:1. Blasts were defined as viable/CD45 low /CD123 + /CD33 + /CD117 + or CD34 + /CD117 + . The gating strategy is shown in Supplementary Fig. . Leukemic blast counts of vehicle treatment without NK cells were set to baseline. E:T ratios of patient’s endogenous NK cells to blasts (in the absence of healthy donor-derived allogeneic NK cells) were 0.1:1, 0.01:1 and 0.2:1 for non-responders and 0.5:1, 0.1:1 and 0.1:1 for responders (data points from top to bottom for 5000 pM AFM28). Data are represented as mean ± SD and were analyzed using one-way ANOVA and Tukey’s multiple comparisons test. B BMMC samples derived from a single AML patient were treated with 0–500 pM of AFM28 for 24 h in the presence of allogeneic AML patient-derived NK cells ( n = 5) or healthy donor-derived NK cells ( n = 5) at a 1:1 E:T ratio. Analysis was performed using flow cytometry. Blasts were defined as viable/CD45 low /CD34 + /CD38 + /CD123 + . Blast counts of 0 pM treatment were set to baseline. HY healthy, SD standard deviation.

    Techniques Used: Derivative Assay, Generated, Flow Cytometry, Standard Deviation

    Related Articles

    Isolation:

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells.
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1a cells and primary AML cells by CD34+CD38– Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1a cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.

    Article Title: Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 10 4 human cord blood unit (CBU)-derived CD34 + cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34 + cells were isolated using CD34 + cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL-15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1α cells and primary AML cells by CD34 + CD38 – Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1α cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.

    Cell Isolation:

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells.
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1a cells and primary AML cells by CD34+CD38– Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1a cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.

    Article Title: Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia.
    Article Snippet: ETPs were isolated by inmunomagnetic sorting from postnatal thymocyte suspensions obtained by centrifugation on Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS) using the Dynal CD34 Progenitor Cell Selection System (Life Technologies). .. HPCs were obtained from Ficoll-Hypaque-purified cord blood samples using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec)40. ..

    Article Title: Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 10 4 human cord blood unit (CBU)-derived CD34 + cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34 + cells were isolated using CD34 + cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL-15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1α cells and primary AML cells by CD34 + CD38 – Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1α cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.

    Article Title: Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia
    Article Snippet: ETPs were isolated by inmunomagnetic sorting from postnatal thymocyte suspensions obtained by centrifugation on Ficoll-Hypaque (Lymphoprep, Axis-Shield PoC AS) using the Dynal CD34 Progenitor Cell Selection System (Life Technologies). .. HPCs were obtained from Ficoll-Hypaque-purified cord blood samples using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec) . ..

    Magnetic Cell Separation:

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells.
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1a cells and primary AML cells by CD34+CD38– Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1a cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.

    Article Title: cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells
    Article Snippet: Primary NK cells were cultured in RPMI-1640 Medium, complemented with 10% FBS (Gibco, Australia), 200 IU/mL rhIL-2 (Beyotime, China), 10 ng/mL rhIL-15 (Beyotime, China) and 1% penicillin and streptomycin. .. The LSCs were isolated from KG-1α cells and primary AML cells by CD34 + CD38 – Cell Isolation Kit (Cat#: 130-114-822, Miltenyi Biotec) via MACS Separation as instructions. .. Briefly, KG-1α cells or primary AML cells were collected in cold medium by centrifuge at 300×g for 10 minutes, following by the steps sequentially: First magnetic labeling (incubation with CD34 MultiSort MicroBeads)-First magnetic separation-Removal of MultiSort MicroBeads and second magnetic labeling (incubation with CD34 MultiSort MicroBeads and CD38 MicroBeads)-Second magnetic separation with LS Columns.



    Similar Products

    cd34 cd38 cell isolation kit  (Miltenyi Biotec)
    95
    Miltenyi Biotec cd34 cd38 cell isolation kit
    Cd34 Cd38 Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pm41809821-64-12-18
    Average 95 stars, based on 1 article reviews
    cd34 cd38 cell isolation kit - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    cd34 cell isolation  (Miltenyi Biotec)
    97
    Miltenyi Biotec cd34 cell isolation
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Cell Isolation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pmc12960979-313-1-12
    Average 97 stars, based on 1 article reviews
    cd34 cell isolation - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    direct cd34 progenitor cell isolation kit  (Miltenyi Biotec)
    97
    Miltenyi Biotec direct cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Direct Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pm41288024-53-49-56
    Average 97 stars, based on 1 article reviews
    direct cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    human cd34 progenitor cell isolation kit  (Miltenyi Biotec)
    97
    Miltenyi Biotec human cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/CD34+MicroBead+Kit%2C+human/pmc12628175__mmc3-354-29-35
    Average 97 stars, based on 1 article reviews
    human cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    cd34 progenitor cell isolation kit  (Miltenyi Biotec)
    94
    Miltenyi Biotec cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/Diamond+CD34+Isolation+Kit%2C+human/us12453770-1672-33-38
    Average 94 stars, based on 1 article reviews
    cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human cd34 microbeads kit miltenyi biotec  (Miltenyi Biotec)
    97
    Miltenyi Biotec human cd34 microbeads kit miltenyi biotec
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Microbeads Kit Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation/NK+Cell+Isolation+Kit%2C+human/pm40803321-1327-105-109
    Average 97 stars, based on 1 article reviews
    human cd34 microbeads kit miltenyi biotec - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Circadian fluctuation of soluble CD26 dictates the impact of the timing of cord blood transplantation on acute graft-versus-host disease

    doi: 10.1038/s41467-026-68958-4

    Figure Lengend Snippet: a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Article Snippet: For CD34+ cell isolation, immunomagnetic depletion was performed via CD34 microbeads (130-046-702, Miltenyi Biotech) following the recommended protocol.

    Techniques: Transplantation Assay